Information

4.8D: Extracellular Matrix of Animal Cells - Biology

4.8D: Extracellular Matrix of Animal Cells - Biology


We are searching data for your request:

Forums and discussions:
Manuals and reference books:
Data from registers:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

The extracellular matrix of animal cells holds cells together to form a tissue and allow tissues to communicate with each other.

LEARNING OBJECTIVES

Explain the role of the extracellular matrix in animal cells

Key Points

  • The extracellular matrix of animal cells is made up of proteins and carbohydrates.
  • Cell communication within tissue and tissue formation are main functions of the extracellular matrix of animal cells.
  • Tissue communication is kick-started when a molecule within the matrix binds a receptor; the end results are conformational changes that induce chemical signals that ultimately change activities within the cell.

Key Terms

  • collagen: Any of more than 28 types of glycoprotein that forms elongated fibers, usually found in the extracellular matrix of connective tissue.
  • proteoglycan: Any of many glycoproteins that have heteropolysaccharide side chains
  • extracellular matrix: All the connective tissues and fibres that are not part of a cell, but rather provide support.

Extracellular Matrix of Animal Cells

Most animal cells release materials into the extracellular space. The primary components of these materials are proteins. Collagen is the most abundant of the proteins. Its fibers are interwoven with carbohydrate-containing protein molecules called proteoglycans. Collectively, these materials are called the extracellular matrix. Not only does the extracellular matrix hold the cells together to form a tissue, but it also allows the cells within the tissue to communicate with each other.

How does this cell communication occur? Cells have protein receptors on the extracellular surfaces of their plasma membranes. When a molecule within the matrix binds to the receptor, it changes the molecular structure of the receptor. The receptor, in turn, changes the conformation of the microfilaments positioned just inside the plasma membrane. These conformational changes induce chemical signals inside the cell that reach the nucleus and turn “on” or “off” the transcription of specific sections of DNA. This affects the production of associated proteins, thus changing the activities within the cell.

An example of the role of the extracellular matrix in cell communication can be seen in blood clotting. When the cells lining a blood vessel are damaged, they display a protein receptor called tissue factor. When a tissue factor binds with another factor in the extracellular matrix, it causes platelets to adhere to the wall of the damaged blood vessel and stimulates the adjacent smooth muscle cells in the blood vessel to contract (thus constricting the blood vessel). Subsequently, a series of steps are initiated which then prompt the platelets to produce clotting factors.


Publications by authors named "Anna Dikalova"

J Physiol 2021 Jun 26599(12):3013-3036. Epub 2021 May 26.

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.

Key Points: LRRC8A-containing anion channels associate with NADPH oxidase 1 (Nox1) and regulate superoxide production and tumour necrosis factor-α (TNFα) signalling. Here we show that LRRC8C and 8D also co-immunoprecipitate with Nox1 in vascular smooth muscle cells. LRRC8C knockdown inhibited TNFα-induced O production, receptor endocytosis, nuclear factor-κB (NF-κB) activation and proliferation while LRRC8D knockdown enhanced NF-κB activation. Significant changes in LRRC8 isoform expression in human atherosclerosis and psoriasis suggest compensation for increased inflammation. The oxidant chloramine-T (ChlorT, 1 mM) weakly (∼25%) inhibited LRRC8C currents but potently (∼80%) inhibited LRRC8D currents. Substitution of the extracellular loop (EL1, EL2) domains of 8D into 8C conferred significantly stronger (69%) ChlorT-dependent inhibition. ChlorT exposure impaired subsequent current block by DCPIB, which occurs through interaction with EL1, further implicating external oxidation sites. LRRC8A/C channels most effectively sustain Nox1 activity at the plasma membrane. This may result from their ability to remain active in an oxidized microenvironment.

Abstract: Tumour necrosis factor-α (TNFα) activates NADPH oxidase 1 (Nox1) in vascular smooth muscle cells (VSMCs), producing superoxide (O ) required for subsequent signalling. LRRC8 family proteins A-E comprise volume-regulated anion channels (VRACs). The required subunit LRRC8A physically associates with Nox1, and VRAC activity is required for Nox activity and the inflammatory response to TNFα. VRAC currents are modulated by oxidants, suggesting that channel oxidant sensitivity and proximity to Nox1 may play a physiologically relevant role. In VSMCs, LRRC8C knockdown (siRNA) recapitulated the effects of siLRRC8A, inhibiting TNFα-induced extracellular and endosomal O production, receptor endocytosis, nuclear factor-κB (NF-κB) activation and proliferation. In contrast, siLRRC8D potentiated NF-κB activation. Nox1 co-immunoprecipitated with 8C and 8D, and colocalized with 8D at the plasma membrane and in vesicles. We compared VRAC currents mediated by homomeric and heteromeric LRRC8C and LRRC8D channels expressed in HEK293 cells. The oxidant chloramine T (ChlorT, 1 mM) weakly inhibited 8C, but potently inhibited 8D currents. ChlorT exposure also impaired subsequent current block by the VRAC blocker DCPIB, implicating external sites of oxidation. Substitution of the 8D extracellular loop domains (EL1, EL2) into 8C conferred significantly stronger ChlorT-mediated inhibition of 8C currents. Our results suggest that LRRC8A/C channel activity can be effectively maintained in the oxidized microenvironment expected to result from Nox1 activation at the plasma membrane. Increased ratios of 8D:8C expression may potentially depress inflammatory responses to TNFα. LRRC8A/C channel downregulation represents a novel strategy to reduce TNFα-induced inflammation.

Download full-text PDF

Mitochondrial Isolevuglandins Contribute to Vascular Oxidative Stress and Mitochondria-Targeted Scavenger of Isolevuglandins Reduces Mitochondrial Dysfunction and Hypertension.

Authors:

Hypertension 2020 12 576(6):1980-1991. Epub 2020 Oct 5.

From the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).

Download full-text PDF

Response by Dikalova and Dikalov to Letter Regarding Article, "Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress".

Authors:

Circ Res 2020 03 26126(7):e33-e34. Epub 2020 Mar 26.

From the Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.

Download full-text PDF

Combined l-citrulline and tetrahydrobiopterin therapy improves NO signaling and ameliorates chronic hypoxia-induced pulmonary hypertension in newborn pigs.

Authors:

Am J Physiol Lung Cell Mol Physiol 2020 04 19318(4):L762-L772. Epub 2020 Feb 19.

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.

Download full-text PDF

Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress.

Authors:

Circ Res 2020 02 19126(4):439-452. Epub 2019 Dec 19.

From the Vanderbilt University Medical Center, Nashville, TN (A.E.D., A.P., L.X., L.A., T.S., M.G.L., F.T.B., D.G.H., S.I.D.).

Rationale: Hypertension represents a major risk factor for stroke, myocardial infarction, and heart failure and affects 30% of the adult population. Mitochondrial dysfunction contributes to hypertension, but specific mechanisms are unclear. The mitochondrial deacetylase Sirt3 (Sirtuin 3) is critical in the regulation of metabolic and antioxidant functions which are associated with hypertension, and cardiovascular disease risk factors diminish Sirt3 level.

Objective: We hypothesized that reduced Sirt3 expression contributes to vascular dysfunction in hypertension, but increased Sirt3 protects vascular function and decreases hypertension.

Methods And Results: To test the therapeutic potential of targeting Sirt3 expression, we developed new transgenic mice with global Sirt3OX (Sirt3 overexpression), which protects from endothelial dysfunction, vascular oxidative stress, and hypertrophy and attenuates Ang II (angiotensin II) and deoxycorticosterone acetate-salt induced hypertension. Global Sirt3 depletion in mice results in oxidative stress due to hyperacetylation of mitochondrial superoxide dismutase (SOD2), increases HIF1α (hypoxia-inducible factor-1), reduces endothelial cadherin, stimulates vascular hypertrophy, increases vascular permeability and vascular inflammation (p65, caspase 1, VCAM [vascular cell adhesion molecule-1], ICAM [intercellular adhesion molecule-1], and MCP1 [monocyte chemoattractant protein 1]), increases inflammatory cell infiltration in the kidney, reduces telomerase expression, and accelerates vascular senescence and age-dependent hypertension conversely, increased Sirt3 expression in Sirt3OX mice prevents these deleterious effects. The clinical relevance of Sirt3 depletion was confirmed in arterioles from human mediastinal fat in patients with essential hypertension showing a 40% decrease in vascular Sirt3, coupled with Sirt3-dependent 3-fold increases in SOD2 acetylation, NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activity, VCAM, ICAM, and MCP1 levels in hypertensive subjects compared with normotensive subjects.

Conclusions: We suggest that Sirt3 depletion in hypertension promotes endothelial dysfunction, vascular hypertrophy, vascular inflammation, and end-organ damage. Our data support a therapeutic potential of targeting Sirt3 expression in vascular dysfunction and hypertension.


Introduction

Protozoa from the genus Acanthamoeba have been isolated from distinct environments around the world, such as soil, water reservoirs, public toilets or environmental water sources, such as lakes and rivers [ 1 , 2 ]. Medical devices, i.e., heart valves [ 3 ] and contact lenses, are also platforms for the growth of Acanthamoeba sp. the last mainly by the usage of contaminated cleaning solutions [ 4–6 ].

The Acanthamoeba genus is comprised of single-celled microorganisms, which features two distinct phases of life cycle: the free-living and metabolically active stage trophozoites and the resistant phase stage called cyst. The parasitic trophozoites are motile and display spiny-like projections on their surfaces, called acanthapodia. These movements are important for Acanthamoeba nutrient acquisition, which happens essentially by phagocytosis of bacteria or yeasts. On the other hand, the non-motile cyst form has a double-layered wall, which provides resistance to environmental adversities such as extremes of pH, high temperatures and antimicrobials [ 6–9 ].

Acanthamoeba sp. infections are associated with a broad range of clinical presentations in humans, but the most common conditions involve the eye and central nervous system infections [ 6 , 10–12 ]. Acanthamoeba keratitis is one of the most common and serious clinical manifestations caused by this organism, followed by encephalitis both can cause irreversible damage if not treated properly [ 10 , 11 , 13–15 ].

Several molecules have been described to have a role on Acanthamoeba pathogenesis, helping the protozoa to invade the host tissue and escape their defense mechanisms [ 16 , 17 ]. The secretion of glycoproteins, proteases and others molecules was correlated with the pathogenic potential of these organisms [ 18 ]. Among these components, proteases have been documented as the major virulence factors and could mediate host tissue destruction and digestion of phagocytosed particles within the microorganism [ 19–21 ]. In addition to the effects of proteases such as elastases, metalloproteases, serine and cysteine proteases regarding tissue invasion [ 21–26 ], they are also directly related to mannose-binding proteins mediated adhesion, playing important role in the interaction of Acanthamoeba and the host cell.

In recent years, extracellular vesicles (EVs) have been described as secretion mechanisms for a wide range of molecules to reach the extracellular environment in a large number of organisms [ 27–31 ]. The cellular origin of these vesicular molecules and the exact mechanism by which they are produced are yet to be determined, although numerous studies suggest that this process involves components of both conventional and non-conventional secretion pathways [ 32–34 ]. However, morphological and biochemical characteristics indicate that they are similar to those described in several mammalian cells [ 35 ], containing lipids, nucleic acids, protein and polysaccharide components [ 31 , 36–38 ]. In the case of important human fungal pathogens, many of those components are associated with virulence [ 33 , 36 , 37 , 39 , 40 ].

The production of EVs have also been described in such protozoa as Plasmodium sp [ 41 ]., Leishmania donovani and L. major [ 42 , 43 ], Trypanosoma brucei [ 44 , 45 ], T. cruzii [ 46 , 47 ], in helmints such as the nematodes Echinostoma caproni and Fasciola hepatica [ 48 ], Helingmosomoides polygrus [ 49 ], Teladorsagia circumcincta [ 50 ], the trematode Dicrocoelium dendriticum [ 51 ] and the amoeba Dictyostelium discoideum [ 52 ]. Some reports have stated the importance of these exosomes during host-parasite interaction, working as communication mediators between the different cells from distinct organisms, therefore bearing a potential therapeutic target for infectious diseases [ 40 , 41 ].

The secretory mechanisms used by amoebas are still unclear, but there is a parallel to the release of exosomes described in eukaryotes such as parasites, fungi and mammals [ 53–56 ]. In these models, EVs have been described to be involved in the secretion of proteinases into the extracellular environment, with important implications for the pathogenesis and virulence [ 18 , 40 , 41 , 57 ] EVs from Acanthamoeba sp. may contain important virulence factors which, when secreted, could also damage host tissues. Our goal in this study was to characterize the EVs produced and secreted by A. castellanii. As this organism can be found, either within the host or in the environment, in several locations with the most diverse protein concentrations, we characterized the secretome profile of A. castellanii, including the isolation EVs and EV-free fractions, in conditions of distinct availability of protein sources. As EVs were taken up by host cells, the damaging potential and lethal activity of EVs and EVs-free supernatant to host cells were evaluated. Our results suggest the participation of the secretome of A. castellanii on pathogenesis, which could provide a new option for the therapeutic interventions of A. castellanii infections.


Publications by authors named "Fred S Lamb"

J Physiol 2021 Jun 26599(12):3013-3036. Epub 2021 May 26.

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.

Key Points: LRRC8A-containing anion channels associate with NADPH oxidase 1 (Nox1) and regulate superoxide production and tumour necrosis factor-α (TNFα) signalling. Here we show that LRRC8C and 8D also co-immunoprecipitate with Nox1 in vascular smooth muscle cells. LRRC8C knockdown inhibited TNFα-induced O production, receptor endocytosis, nuclear factor-κB (NF-κB) activation and proliferation while LRRC8D knockdown enhanced NF-κB activation. Significant changes in LRRC8 isoform expression in human atherosclerosis and psoriasis suggest compensation for increased inflammation. The oxidant chloramine-T (ChlorT, 1 mM) weakly (∼25%) inhibited LRRC8C currents but potently (∼80%) inhibited LRRC8D currents. Substitution of the extracellular loop (EL1, EL2) domains of 8D into 8C conferred significantly stronger (69%) ChlorT-dependent inhibition. ChlorT exposure impaired subsequent current block by DCPIB, which occurs through interaction with EL1, further implicating external oxidation sites. LRRC8A/C channels most effectively sustain Nox1 activity at the plasma membrane. This may result from their ability to remain active in an oxidized microenvironment.

Abstract: Tumour necrosis factor-α (TNFα) activates NADPH oxidase 1 (Nox1) in vascular smooth muscle cells (VSMCs), producing superoxide (O ) required for subsequent signalling. LRRC8 family proteins A-E comprise volume-regulated anion channels (VRACs). The required subunit LRRC8A physically associates with Nox1, and VRAC activity is required for Nox activity and the inflammatory response to TNFα. VRAC currents are modulated by oxidants, suggesting that channel oxidant sensitivity and proximity to Nox1 may play a physiologically relevant role. In VSMCs, LRRC8C knockdown (siRNA) recapitulated the effects of siLRRC8A, inhibiting TNFα-induced extracellular and endosomal O production, receptor endocytosis, nuclear factor-κB (NF-κB) activation and proliferation. In contrast, siLRRC8D potentiated NF-κB activation. Nox1 co-immunoprecipitated with 8C and 8D, and colocalized with 8D at the plasma membrane and in vesicles. We compared VRAC currents mediated by homomeric and heteromeric LRRC8C and LRRC8D channels expressed in HEK293 cells. The oxidant chloramine T (ChlorT, 1 mM) weakly inhibited 8C, but potently inhibited 8D currents. ChlorT exposure also impaired subsequent current block by the VRAC blocker DCPIB, implicating external sites of oxidation. Substitution of the 8D extracellular loop domains (EL1, EL2) into 8C conferred significantly stronger ChlorT-mediated inhibition of 8C currents. Our results suggest that LRRC8A/C channel activity can be effectively maintained in the oxidized microenvironment expected to result from Nox1 activation at the plasma membrane. Increased ratios of 8D:8C expression may potentially depress inflammatory responses to TNFα. LRRC8A/C channel downregulation represents a novel strategy to reduce TNFα-induced inflammation.

Download full-text PDF

Apoptosis signal-regulating kinase 1 (ASK1) inhibition reduces endothelial cytokine production without improving permeability after toll-like receptor 4 (TLR4) challenge.

Authors:

Transl Res 2021 Apr 20. Epub 2021 Apr 20.

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address:

Download full-text PDF

The Inverse Relationship Between Endothelium-Dependent Vasodilation and Blood Pressure is Lost After Cardiopulmonary Bypass.

Authors:

J Cardiovasc Transl Res 2021 Apr 9. Epub 2021 Apr 9.

Department of Pediatric Critical Care, Vanderbilt University Medical Center, 2200 Children's Way, 5121 Doctors' Office Tower, Nashville, TN, 37232-9075, USA.

Download full-text PDF

TNFα and Reactive Oxygen Signaling in Vascular Smooth Muscle Cells in Hypertension and Atherosclerosis.

Authors:

Am J Hypertens 2020 1033(10):902-913

Division of Pediatric Critical Care, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.


References

Bissell, M. J., Hall, H. G. & Parry, G. How does the extracellular matrix direct gene expression? J. Theor. Biol. 99, 31–68 (1982).

Engler, A. J., Sen, S., Sweeney, H. L. & Discher, D. E. Matrix elasticity directs stem cell lineage specification. Cell 126, 677–689 (2006).

Aitken, K. J. & Bägli, D. J. The bladder extracellular matrix. Part II: regenerative applications. Nat. Rev. Urol. 6, 612–621 (2009).

Chang, S. L., Howard, P. S., Koo, H. P. & Macarak, E. J. Role of type III collagen in bladder filling. Neurourol. Urodyn. 17, 135–145 (1998).

Longhurst, P. A., Eika, B., Leggett, R. E. & Levin, R. M. Urinary bladder function in the tight-skin mouse. J. Urol. 148, 1611–1614 (1992).

Liapis, A. et al. Changes in the quantity of collagen type I in women with genuine stress incontinence. Urol. Res. 28, 323–326 (2000).

Liu, X., Wu, H., Byrne, M., Krane, S. & Jaenisch, R. Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc. Natl Acad. Sci. USA 94, 1852–1856 (1997).

Stevenson, K., Kucich, U., Whitbeck, C., Levin, R. M. & Howard, P. S. Functional changes in bladder tissue from type III collagen-deficient mice. Mol. Cell Biochem. 283, 107–114 (2006).

Saban, R. et al. Bladder inflammatory transcriptome in response to tachykinins: neurokinin 1 receptor-dependent genes and transcription regulatory elements. BMC Urol. 7, 7 (2007).

Strauss, L. et al. Distribution of collagen XII and XIV in the bladder wall of the male rat with outlet obstruction. J. Urol. 163, 1304–1308 (2000).

McMahon, A. P. et al. GUDMAP: the genitourinary developmental molecular anatomy project. J. Am. Soc. Nephrol. 19, 667–671 (2008).

Capolicchio, G., Aitken, K. J., Gu, J. X., Reddy, P. & Bägli, D. J. Extracellular matrix gene responses in a novel ex vivo model of bladder stretch injury. J. Urol. 165, 2235–2240 (2001).

Brown, A. L. et al. Bladder acellular matrix as a substrate for studying in vitro bladder smooth muscle–urothelial cell interactions. Biomaterials 26, 529–543 (2005).

Hinek, A. & Rabinovitch, M. 67 kD elastin-binding protein is a protective “companion” of extracellular insoluble elastin and intracellular tropoelastin. J. Cell Biol. 126, 563–574 (1994).

Mithieux, S. M. & Weiss, A. S. Elastin. Adv. Protein Chem. 70, 437–461 (2005).

Koo, H. P., Macarak, E. J., Chang, S. L., Rosenbloom, J. & Howard, P. S. Temporal expression of elastic fiber components in bladder development. Connect. Tissue Res. 37, 1–11 (1998).

Rosenbloom, J. et al. Expression of microfibrillar proteins by bovine bladder urothelium. Urology 49, 287–292 (1997).

Yang, R., Amir, J., Liu, H. & Chaqour, B. Mechanical strain activates a program of genes functionally involved in paracrine signaling of angiogenesis. Physiol. Genomics 36, 1–14 (2008).

Lemack, G. E. et al. Altered bladder function in transgenic mice expressing rat elastin. Neurourol. Urodyn. 18, 55–68 (1999).

Wipff, J., Allanore, Y. & Boileau, C. Interactions between fibrillin-1 and TGF-β: consequences and human pathology [French]. Med. Sci. (Paris) 25, 161–167 (2009).

Spofford, C. M. & Chilian, W. M. The elastin laminin receptor functions as a mechanotransducer in vascular smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 280, H1354–H1360 (2001).

Hoffman, A. S., Grande, L. A. & Park, J. B. Sequential enzymolysis of human aorta and resultant stress-strain behavior. Biomater. Med. Devices Artif. Organs 5, 121–145 (1977).

Mochizuki, S., Brassart, B. & Hinek, A. Signaling pathways transduced through the elastin receptor facilitate proliferation of arterial smooth muscle cells. J. Biol. Chem. 277, 44854–44863 (2002).

Smeulders, N., Woolf, A. S. & Wilcox, D. T. Extracellular matrix protein expression during mouse detrusor development. J. Pediatr. Surg. 38, 1–12 (2003).

Johansson, R. & Persson, K. Phenotypic modulation of cultured bladder smooth muscle cells and the expression of inducible nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R642–R648 (2004).

Hubschmid, U., Leong-Morgenthaler, P. M., Basset-Dardare, A., Ruault, S. & Frey, P. In vitro growth of human urinary tract smooth muscle cells on laminin and collagen type I-coated membranes under static and dynamic conditions. Tissue Eng. 11, 161–171 (2005).

Bendeck, M. P. et al. Smooth muscle cell matrix metalloproteinase production is stimulated via αvβ3 integrin. Arterioscler. Thromb. Vasc. Biol. 20, 1467–1472 (2000).

Jalvy, S. et al. Autocrine expression of osteopontin contributes to PDGF-mediated arterial smooth muscle cell migration. Cardiovasc. Res. 75, 738–747 (2007).

Rattazzi, M. et al. Calcification of advanced atherosclerotic lesions in the innominate arteries of ApoE-deficient mice: potential role of chondrocyte-like cells. Arterioscler. Thromb. Vasc. Biol. 25, 1420–1425 (2005).

Speer, M. Y. et al. Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro. Cardiovasc. Res. 66, 324–333 (2005).

Giachelli, C. M., Speer, M. Y., Li, X., Rajachar, R. M. & Yang, H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ. Res. 96, 717–722 (2005).

Arafat, H. A., Wein, A. J. & Chacko, S. Osteopontin gene expression and immunolocalization in the rabbit urinary tract. J. Urol. 167, 746–752 (2002).

Serini, G. et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1. J. Cell Biol. 142, 873–881 (1998).

Little, W. C., Smith, M. L., Ebneter, U. & Vogel, V. Assay to mechanically tune and optically probe fibrillar fibronectin conformations from fully relaxed to breakage. Matrix Biol. 27, 451–461 (2008).

Gee, E. P., Ingber, D. E. & Stultz, C. M. Fibronectin unfolding revisited: modeling cell traction-mediated unfolding of the tenth type-III repeat. PLoS One 3, e2373 (2008).

Krammer, A., Craig, D., Thomas, W. E., Schulten, K. & Vogel, V. A structural model for force regulated integrin binding to fibronectin's RGD-synergy site. Matrix Biol. 21, 139–147 (2002).

Hinek, A. et al. Decreased elastin deposition and high proliferation of fibroblasts from Costello syndrome are related to functional deficiency in the 67 kD elastin-binding protein. Am. J. Hum. Genet. 66, 859–872 (2000).

Hinek, A. & Wilson, S. E. Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am. J. Pathol. 156, 925–938 (2000).

Ständer, M., Naumann, U., Wick, W. & Weller, M. Transforming growth factor-β and p21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res. 296, 221–227 (1999).

Border, W. A. et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 360, 361–364 (1992).

Badylak, S. F., Freytes, D. O. & Gilbert, T. W. Extracellular matrix as a biological scaffold material: structure and function. Acta Biomater. 5, 1–13 (2009).

Adam, S. et al. Binding of fibulin-1 to nidogen depends on its C-terminal globular domain and a specific array of calcium-binding epidermal growth factor-like (EG) modules. J. Mol. Biol. 272, 226–236 (1997).

Kresse, H. et al. Different usage of the glycosaminoglycan attachment sites of biglycan. J. Biol. Chem. 276, 13411–13416 (2001).

Vynios, D. H., Papageorgakopoulou, N., Sazakli, H. & Tsiganos, C. P. The interactions of cartilage proteoglycans with collagens are determined by their structures. Biochimie 83, 899–906 (2001).

Moreno, M. et al. Biglycan is a new extracellular component of the Chordin-BMP4 signaling pathway. EMBO J. 24, 1397–1405 (2005).

Tiitta, O., Wahlström, T., Virtanen, I. & Gould, V. E. Tenascin in inflammatory conditions and neoplasms of the urinary bladder. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 63, 283–287 (1993).

Saga, Y., Tsukamoto, T., Jing, N., Kusakabe, M. & Sakakura, T. Murine tenascin: cDNA cloning, structure and temporal expression of isoforms. Gene 104, 177–185 (1991).

Wilson, C. B., Leopard, J., Cheresh, D. A. & Nakamura, R. M. Extracellular matrix and integrin composition of the normal bladder wall. World J. Urol. 14 (Suppl. 1), S30–S37 (1996).

Jones, P. L., Crack, J. & Rabinovitch, M. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the αvβ3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J. Cell Biol. 139, 279–293 (1997).

Sciandra, F. et al. First molecular characterization and immunolocalization of keratoepithelin in adult human skeletal muscle. Matrix Biol. 27, 360–370 (2008).

Gingras, J. et al. Agrin becomes concentrated at neuroeffector junctions in developing rodent urinary bladder. Cell Tissue Res. 320, 115–125 (2005).

Erickson, D. R., Schwarze, S. R., Dixon, J. K., Clark, C. J. & Hersh, M. A. Differentiation associated changes in gene expression profiles of interstitial cystitis and control urothelial cells. J. Urol. 180, 2681–2687 (2008).

Heino, J. The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol. 19, 319–323 (2000).

Lal, H. et al. Integrins: novel therapeutic targets for cardiovascular diseases. Cardiovasc. Hematol. Agents Med. Chem. 5, 109–132 (2007).

Brancaccio, M. et al. Integrin signaling: the tug-of-war in heart hypertrophy. Cardiovasc. Res. 70, 422–433 (2006).

Romer, L. H., Birukov, K. G. & Garcia, J. G. Focal adhesions: paradigm for a signaling nexus. Circ. Res. 98, 606–616 (2006).

Southgate, J., Kennedy, W., Hutton, K. A. & Trejdosiewicz, L. K. Expression and in vitro regulation of integrins by normal human urothelial cells. Cell Adhes. Commun. 3, 231–242 (1995).

Upadhyay, J., Aitken, K. J., Damdar, C., Bolduc, S. & Bägli, D. J. Integrins expressed with bladder extracellular matrix after stretch injury in vivo mediate bladder smooth muscle cell growth in vitro. J. Urol. 169, 750–755 (2003).

Ozturk, H., Ozturk, H., Guneli, E., Yagmur, Y. & Buyukbayram, H. Expression of CD44 and E cadherin cell adhesion molecules in hypertrophied bladders during chronic partial urethral obstruction and after release of partial obstruction in rats. Urology 65, 1013–1018 (2005).

Yu, W. H., Woessner, J. F. Jr, McNeish, J. D. & Stamenkovic, I. CD44 anchors the assembly of matrilysin/MMP 7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. 16, 307–323 (2002).

Acharya, P. S. et al. Fibroblast migration is mediated by CD44-dependent TGF beta activation. J. Cell Sci. 121, 1393–1402 (2008).

Miyamoto, A., Lau, R., Hein, P. W., Shipley, J. M. & Weinmaster, G. Microfibrillar proteins MAGP-1 and MAGP-2 induce Notch1 extracellular domain dissociation and receptor activation. J. Biol. Chem. 281, 10089–10097 (2006).

Hodkinson, P. S. et al. Mammalian NOTCH-1 activates β1 integrins via the small GTPase R-Ras. J. Biol. Chem. 282, 28991–29001 (2007).

Bägli, D. J., Joyner, B. D., Mahoney, S. R. & McCulloch, L. The hyaluronic acid receptor RHAMM is induced by stretch injury of rat bladder in vivo and influences smooth muscle cell contraction in vitro [corrected]. J. Urol. 162, 832–840 (1999).

Ferri, N., Carragher, N. O. & Raines, E. W. Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis. Am. J. Pathol. 164, 1575–1585 (2004).

Blissett, A. R. et al. Regulation of collagen fibrillogenesis by cell-surface expression of kinase dead DDR2. J. Mol. Biol. 385, 902–911 (2009).

Vogel, W., Gish, G. D., Alves, F. & Pawson, T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol. Cell 1, 13–23 (1997).

Konitsiotis, A. D. et al. Characterization of high affinity binding motifs for the discoidin domain receptor DDR2 in collagen. J. Biol. Chem. 283, 6861–6868 (2008).

Leitinger, B. & Kwan, A. P. The discoidin domain receptor DDR2 is a receptor for type X collagen. Matrix Biol. 25, 355–364 (2006).

GUDMAP:10746. Ddr2 discoidin domain receptor family, member 2. Stage TS23. Genitourinary Development Molecular Anatomy Project [online], (2009).

Hinek, A., Keeley, F. W. & Callahan, J. Recycling of the 67 kDa elastin binding protein in arterial myocytes is imperative for secretion of tropoelastin. Exp. Cell Res. 220, 312–324 (1995).

Privitera, S., Prody, C. A., Callahan, J. W. & Hinek, A. The 67 kDa enzymatically inactive alternatively spliced variant of β-galactosidase is identical to the elastin/laminin-binding protein. J. Biol. Chem. 273, 6319–6326 (1998).

Hinek, A., Braun, K. R., Liu, K., Wang, Y. & Wight, T. N. Retrovirally mediated overexpression of versican v3 reverses impaired elastogenesis and heightened proliferation exhibited by fibroblasts from Costello syndrome and Hurler disease patients. Am. J. Pathol. 164, 119–131 (2004).

Hinek, A., Boyle, J. & Rabinovitch, M. Vascular smooth muscle cell detachment from elastin and migration through elastic laminae is promoted by chondroitin sulfate-induced “shedding” of the 67 kDa cell surface elastin binding protein. Exp. Cell Res. 203, 344–353 (1992).

Hinek, A. Biological roles of the non-integrin elastin/laminin receptor. Biol. Chem. 377, 471–480 (1996).

Spofford, C. M. & Chilian, W. M. Mechanotransduction via the elastin-laminin receptor (ELR) in resistance arteries. J. Biomech. 36, 645–652 (2003).

Wilson, E., Sudhir, K. & Ives, H. E. Mechanical strain of rat vascular smooth muscle cells is sensed by specific extracellular matrix/integrin interactions. J. Clin. Invest. 96, 2364–2372 (1995).

Lucero, H. A. & Kagan, H. M. Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell. Mol. Life Sci. 63, 2304–2316 (2006).

Lelièvre, E. et al. VE-statin/EGFL7 regulates vascular elastogenesis by interacting with lysyl oxidases. EMBO J. 27, 1658–1670 (2008).

Lee, U. J. et al. Lower urogenital tract anatomical and functional phenotype in lysyl oxidase like-1 knockout mice resembles female pelvic floor dysfunction in humans. Am. J. Physiol. Renal Physiol. 295, F545–F555 (2008).

Liu, X., Zhao, Y., Pawlyk, B., Damaser, M. & Li, T. Failure of elastic fiber homeostasis leads to pelvic floor disorders. Am. J. Pathol. 168, 519–528 (2006).

Liu, X. et al. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat. Genet. 36, 178–182 (2004).

Mäki, J. M. et al. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 106, 2503–2509 (2002).

Hornstra, I. K. et al. Lysyl oxidase is required for vascular and diaphragmatic development in mice. J. Biol. Chem. 278, 14387–14393 (2003).

Paszek, M. J. et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 8, 241–254 (2005).

Matsumoto, K., Fujiwara, Y., Nagai, R. & Yoshida, M. Immunohistochemical detection of advanced glycation end products in human bladder with specific monoclonal antibody. Int. J. Urol. 16, 402–405 (2009).

Winlove, C. P., Parker, K. H., Avery, N. C. & Bailey, A. J. Interactions of elastin and aorta with sugars in vitro and their effects on biochemical and physical properties. Diabetologia 39, 1131–1139 (1996).

Furber, J. D. Extracellular glycation crosslinks: prospects for removal. Rejuvenation Res. 9, 274–278 (2006).

Spoerl, E., Mrochen, M., Sliney, D., Trokel, S. & Seiler, T. Safety of UVA-riboflavin cross-linking of the cornea. Cornea 26, 385–389 (2007).

Sutherland, R. S., Baskin, L. S., Elfman, F., Hayward, S. W. & Cunha, G. R. The role of type IV collagenases in rat bladder development and obstruction. Pediatr. Res. 41, 430–434 (1997).

Hipp, J. D. et al. Using gene chips to identify organ-specific, smooth muscle responses to experimental diabetes: potential applications to urological diseases. BJU Int. 99, 418–430 (2007).

Aitken, K. et al. Mammalian target of rapamycin (mTOR) induces proliferation and de-differentiation responses to three coordinate pathophysiologic stimuli (mechanical strain, hypoxia, and extracellular matrix remodeling) in rat bladder smooth muscle. Am. J. Pathol. (in press).

Backhaus, B. O. et al. Alterations in the molecular determinants of bladder compliance at hydrostatic pressures less than 40 cmH2O. J. Urol. 168, 2600–2604 (2002).

Franco, C. et al. Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices. Am. J. Pathol. 168, 1697–1709 (2006).

Daley, W. P., Peters, S. B. & Larsen, M. Extracellular matrix dynamics in development and regenerative medicine. J. Cell Sci. 121, 255–264 (2008).

Shiroyanagi, Y. et al. Urothelial sonic hedgehog signaling plays an important role in bladder smooth muscle formation. Differentiation 75, 968–977 (2007).

Haraguchi, R. et al. Molecular analysis of coordinated bladder and urogenital organ formation by Hedgehog signaling. Development 134, 525–533 (2007).

Cheng, W. et al. Sonic hedgehog mediator Gli2 regulates bladder mesenchymal patterning. J. Urol. 180, 1543–1550 (2008).

Sasaki, Y., Iwai, N., Tsuda, T. & Kimura, O. Sonic hedgehog and bone morphogenetic protein 4 expressions in the hindgut region of murine embryos with anorectal malformations. J. Pediatr. Surg. 39, 170–173 (2004).

Wu, H. Y., Baskin, L. S., Blakey, C., Goodman, J. & Cunha, G. R. Ultrastructural smooth muscle ontogeny of the rat bladder. Adv. Exp. Med. Biol. 462, 93–102 (1999).

Wagg, A. & Fry, C. H. Visco-elastic properties of isolated detrusor smooth muscle. Scand. J. Urol. Nephrol. Suppl. 201, 12–18 (1999).

Howlett, A. R., Hodges, G. M. & Rowlatt, C. Epithelial–stromal interactions in the adult bladder: urothelial growth, differentiation, and maturation on culture facsimiles of bladder stroma. Dev. Biol. 118, 403–415 (1986).

Oottamasathien, S. et al. Bladder tissue formation from cultured bladder urothelium. Dev. Dyn. 235, 2795–2801 (2006).

Baskin, L. S. et al. Cellular signaling in the bladder. Front. Biosci. 2, d592–d595 (1997).

Master, V. A., Wei, G., Liu, W. & Baskin, L. S. Urothlelium facilitates the recruitment and trans-differentiation of fibroblasts into smooth muscle in acellular matrix. J. Urol. 170, 1628–1632 (2003).

Glukhova, M. A., Frid, M. G., Shekhonin, B. V., Balabanov, Y. V. & Koteliansky, V. E. Expression of fibronectin variants in vascular and visceral smooth muscle cells in development. Dev. Biol. 141, 193–202 (1990).

Le Gat, L. et al. The β3 integrin gene is expressed at high levels in the major haematopoietic and lymphoid organs, vascular system, and skeleton during mouse embryo development. Cell Commun. Adhes. 10, 129–140 (2003).

Baciu, P. C., Suleiman, E. A., Deryugina, E. I. & Strongin, A. Y. Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-αv integrin regulates cross-talk between αvβ3 and α2β1 integrins in breast carcinoma cells. Exp. Cell Res. 291, 167–175 (2003).

Deryugina, E. I., Bourdon, M. A., Jungwirth, K., Smith, J. W. & Strongin, A. Y. Functional activation of integrin αvβ3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int. J. Cancer 86, 15–23 (2000).

Martínez-Morales, J. R. et al. Vitronectin is expressed in the ventral region of the neural tube and promotes the differentiation of motor neurons. Development 124, 5139–5147 (1997).

Pons, S., Trejo, J. L., Martínez-Morales, J. R. & Martí, E. Vitronectin regulates Sonic hedgehog activity during cerebellum development through CREB phosphorylation. Development 128, 1481–1492 (2001).

Berger, T. M., Hirsch, E., Djonov, V. & Schittny, J. C. Loss of β1-integrin-deficient cells during the development of endoderm-derived epithelia. Anat. Embryol. (Berl.) 207, 283–288 (2003).

Baskin, L. S., Sutherland, R. S., Thomson, A. A., Hayward, S. W. & Cunha, G. R. Growth factors and receptors in bladder development and obstruction. Lab. Invest. 75, 157–166 (1996).

Chang, S. L., Chung, J. S., Yeung, M. K., Howard, P. S. & Macarak, E. J. Roles of the lamina propria and the detrusor in tension transfer during bladder filling. Scand. J. Urol. Nephrol. 201 (Suppl.), 38–45 (1999).

GUDMAP:9703. Lgals1 Lectin, galactose binding, soluble 1. Stage TS21. Genitourinary Development Molecular Anatomy Project [online], (2009).

Little, M. H. et al. A high-resolution anatomical ontology of the developing murine genitourinary tract. Gene Expr. Patterns 7, 680–699 (2007).

Hapln1, hyaluronan and proteoglycan link protein 1, bladders expressing fluorescent reporters, gene expression array-based, count. Gene Expression Omnibus Profiles [online], (2009).

Le Goff, C. et al. Regulation of procollagen amino-propeptide processing during mouse embryogenesis by specialization of homologous ADAMTS proteases: insights on collagen biosynthesis and dermatosparaxis. Development 133, 1587–1596 (2006).

Wang, W. M. et al. Transforming growth factor-beta induces secretion of activated ADAMTS 2: a procollagen III N proteinase. J. Biol. Chem. 278, 19549–19557 (2003).

Braun, A. et al. PINCH2 is a new five LIM domain protein, homologous to PINCH and localized to focal adhesions. Exp. Cell Res. 284, 239–250 (2003).

Morrow, D. et al. Sonic Hedgehog induces Notch target gene expression in vascular smooth muscle cells via VEGF-A. Arterioscler. Thromb. Vasc. Biol. 29, 1112–1118 (2009).

Androutsellis-Theotokis, A. et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 442, 823–826 (2006).

Scholzen, T. et al. The murine decorin: complete cDNA cloning, genomic organization, chromosomal assignment, and expression during organogenesis and tissue differentiation. J. Biol. Chem. 269, 28270–28281 (1994).

Bagli, D. J. In Progress in Pediatric Urology Vol. 4 (eds Bajpai, M. et al.) 1–10 (Pennwell Publishers, New Delhi, 2001).

Coulson, W. Coulson on the Diseases of the Bladder and the Prostate Gland (William Wood and Company New York, NY, 1881).

Alloussi, S. H., Muertz, G., Lang, C. & Alloussi, S. Concentric and excentric compensation mechanisms in patients with benign prostatic syndrome—a retrospective analysis of 3162 men with conventional urodynamic/videourodynamic studies [abstract #535]. International Continence Society Annual Meeting. Rotterdam, The Netherlands 20–24 August 2007, http://www.icsoffice.org/publications/2007/pdf/0535.pdf (2007).

Peters, C. A. et al. The effect of obstruction on the developing bladder. J. Urol. 148, 491–496 (1992).

Schröder, A. et al. Effect of chronic bladder outlet obstruction on blood flow of the rabbit bladder. J. Urol. 165, 640–646 (2001).

Kato, K. et al. The functional effects of long-term outlet obstruction on the rabbit urinary bladder. J. Urol. 143, 600–606 (1990).

Landau, E. H. et al. Loss of elasticity in dysfunctional bladders: urodynamic and histochemical correlation. J. Urol. 152, 702–705 (1994).

Inaba, M. et al. Upregulation of heme oxygenase and collagen type III in the rat bladder after partial bladder outlet obstruction. Urol. Int. 78, 270–277 (2007).

Ewalt, D. H. et al. Is lamina propria matrix responsible for normal bladder compliance? J. Urol. 148, 544–549 (1992).

Tekgul, S. et al. Collagen types I and III localization by in situ hybridization and immunohistochemistry in the partially obstructed young rabbit bladder. J. Urol. 156, 582–586 (1996).

Deveaud, C. M. et al. Molecular analysis of collagens in bladder fibrosis. J. Urol. 160, 1518–1527 (1998).

Baskin, L., Howard, P. S. & Macarak, E. Effect of physical forces on bladder smooth muscle and urothelium. J. Urol. 150, 601–607 (1993).

Kaplan, E. P., Richier, J. C., Howard, P. S., Ewalt, D. H. & Lin, V. K. Type III collagen messenger RNA is modulated in non-compliant human bladder tissue. J. Urol. 157, 2366–2369 (1997).

Imamura, M. et al. Basic fibroblast growth factor modulates proliferation and collagen expression in urinary bladder smooth muscle cells. Am. J. Physiol. Renal Physiol. 293, F1007–F1017 (2007).

Levin, R. M., O'Connor, L. J., Leggett, R. E., Whitbeck, C. & Chichester, P. Focal hypoxia of the obstructed rabbit bladder wall correlates with intermediate decompensation. Neurourol. Urodyn. 22, 156–163 (2003).

Buttyan, R., Chen, M. W. & Levin, R. M. Animal models of bladder outlet obstruction and molecular insights into the basis for the development of bladder dysfunction. Eur. Urol. 32 (Suppl. 1), 32–39 (1997).

Lee, S. D. et al. Collagen prolyl 4 hydroxylase is up-regulated in an acute bladder outlet obstruction. J. Pediatr. Urol. 2, 225–232 (2006).

Liu, G. & Daneshgari, F. Temporal diabetes- and diuresis-induced remodeling of the urinary bladder in the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R837–R843 (2006).

Gray, M. A. et al. Time-dependent alterations of select genes in streptozotocin-induced diabetic rat bladder. Urology 71, 1214–1219 (2008).

Yang, L., He, D. L., Wang, S., Cheng, H. P. & Wang, X. Y. Effect of long-term partial bladder outlet obstruction on caldesmon isoforms and their correlation with contractile function. Acta Pharmacol. Sin. 29, 600–605 (2008).

Djavan, B. et al. Decreased elastin gene expression in noncompliant human bladder tissue: a competitive reverse transcriptase-polymerase chain reaction analysis. J. Urol. 160, 1658–1662 (1998).

Nagatomi, J. et al. Early molecular-level changes in rat bladder wall tissue following spinal cord injury. Biochem. Biophys. Res. Commun. 334, 1159–1164 (2005).

Wognum, S., Lagoa, C. E., Nagatomi, J., Sacks, M. S. & Vodovotz, Y. An exploratory pathways analysis of temporal changes induced by spinal cord injury in the rat bladder wall: insights on remodeling and inflammation. PLoS One 4, e5852 (2009).

Jesudason, R., Black, L., Majumdar, A., Stone, P. & Suki, B. Differential effects of static and cyclic stretching during elastase digestion on the mechanical properties of extracellular matrices. J. Appl. Physiol. 103, 803–811 (2007).

Joddar, B. & Ramamurthi, A. Elastogenic effects of exogenous hyaluronan oligosaccharides on vascular smooth muscle cells. Biomaterials 27, 5698–5707 (2006).

Aitken, K. J. et al. Mechanotransduction of extracellular signal-regulated kinases 1 and 2 mitogen-activated protein kinase activity in smooth muscle is dependent on the extracellular matrix and regulated by matrix metalloproteinases. Am. J. Pathol. 169, 459–470 (2006).

Herz, D. B., Aitken, K. & Bagli, D. J. Collagen directly stimulates bladder smooth muscle cell growth in vitro: regulation by extracellular regulated mitogen activated protein kinase. J. Urol. 170, 2072–2076 (2003).

Sabha, N. et al. Matrix metalloproteinase-7 and epidermal growth factor receptor mediate hypoxia-induced extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase activation and subsequent proliferation in bladder smooth muscle cells. In Vitro Cell Dev. Biol. Anim. 42, 124–133 (2006).

Jones, P. L., Jones, F. S., Zhou, B. & Rabinovitch, M. Induction of vascular smooth muscle cell tenascin-C gene expression by denatured type I collagen is dependent upon a β3 integrin-mediated mitogen-activated protein kinase pathway and a 122-base pair promoter element. J. Cell Sci. 112 (Pt 4), 435–445 (1999).

Ghafar, M. A. et al. Hypoxia and an angiogenic response in the partially obstructed rat bladder. Lab. Invest. 82, 903–909 (2002).

Peters, C. A. et al. Dysregulated proteolytic balance as the basis of excess extracellular matrix in fibrotic disease. Am. J. Physiol. 272, R1960–R1965 (1997).

Elkelini, M. S., Aitken, K., Bägli, D. J. & Hassouna, M. M. Effects of doxycycline on voiding behaviour of rats with bladder outlet obstruction. BJU Int. 103, 537–540 (2009).

Brown, J. S. et al. Urologic complications of diabetes. Diabetes Care 28, 177–185 (2005).

Rösen, P., Du, X. & Tschöpe, D. Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by alpha-tocopherol? Mol. Cell. Biochem. 188, 103–111 (1998).

Chang, K. C., Liang, J. T., Tsai, P. S., Wu, M. S. & Hsu, K. L. Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen. Br. J. Pharmacol. 157, 1419–1426 (2009).

Yan, S. F., Ramasamy, R. & Schmidt, A. M. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev. Mol. Med. 11, e9 (2009).

Rittié, L., Berton, A., Monboisse, J. C., Hornebeck, W. & Gillery, P. Decreased contraction of glycated collagen lattices coincides with impaired matrix metalloproteinase production. Biochem. Biophys. Res. Commun. 264, 488–492 (1999).

Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161–174 (2002).

León, H., Baczko, I., Sawicki, G., Light, P. E. & Schulz, R. Inhibition of matrix metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated cardiac myocyte. Br. J. Pharmacol. 153, 676–683 (2008).

Council, L. & Hameed, O. Differential expression of immunohistochemical markers in bladder smooth muscle and myofibroblasts, and the potential utility of desmin, smoothelin, and vimentin in staging of bladder carcinoma. Mod. Pathol. 22, 639–650 (2009).

Ingber, D. E. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ. Res. 91, 877–887 (2002).

Jones, M., Tussey, L., Athanasou, N. & Jackson, D. G. Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. J. Biol. Chem. 275, 7964–7974 (2000).

Fujita, Y. et al. CD44 signaling through focal adhesion kinase and its anti-apoptotic effect. FEBS Lett. 528, 101–108 (2002).

Hipp, J. A., Hipp, J. D., Yoo, J. J., Atala, A. & Andersson, K. E. Microarray analysis of bladder smooth muscle from patients with myelomeningocele. BJU Int. 102, 741–746 (2008).

Lin, H. K. et al. (2004). Characterization of neuropathic bladder smooth muscle cells in culture. J. Urol. 171, 1348–1352 (2004).

Dozmorov, M. G., Kropp, B. P., Hurst, R. E., Cheng, E. Y. & Lin, H. K. Differentially expressed gene networks in cultured smooth muscle cells from normal and neuropathic bladder. J. Smooth Muscle Res. 43, 55–72 (2007).

Halachmi, S. et al. Role of signal transducer and activator of transcription 3 (STAT3) in stretch injury to bladder smooth muscle cells. Cell Tissue Res. 326, 149–158 (2006).

Hauser, P. J., Han, Z., Sindhwani, P. & Hurst, R. E. Sensitivity of bladder cancer cells to curcumin and its derivatives depends on the extracellular matrix. Anticancer Res. 27, 737–740 (2007).

Ratliff, T. L., Palmer, J. O., McGarr, J. A. & Brown, E. J. Intravesical Bacillus Calmette–Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette–Guérin. Cancer Res. 47, 1762–1766 (1987).

Hudson, M. A., Brown, E. J., Ritchey, J. K. & Ratliff, T. L. Modulation of fibronectin-mediated Bacillus Calmette–Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res. 51, 3726–3732 (1991).

Ratliff, T. L., Kavoussi, L. R. & Catalona, W. J. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J. Urol. 139, 410–414 (1988).

Kanayama, H. Matrix metalloproteinases and bladder cancer. J. Med. Invest. 48, 31–43 (2001).

Ioachim, E. et al. Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer 6, 140 (2006).

Hurst, R. E. et al. Proteome-level display by 2-dimensional chromatography of extracellular matrix-dependent modulation of the phenotype of bladder cancer cells. Proteome Sci. 4, 13 (2006).

Cohen, M. B., Griebling, T. L., Ahaghotu, C. A., Rokhlin, O. W. & Ross, J. S. Cellular adhesion molecules in urologic malignancies. Am. J. Clin. Pathol. 107, 56–63 (1997).

Ohyama, C. Glycosylation in bladder cancer. Int. J. Clin. Oncol. 13, 308–313 (2008).

Habuchi, T. et al. Prognostic markers for bladder cancer: international consensus panel on bladder tumor markers. Urology 66, 64–74 (2005).

Sarikaya, A. et al. Antimicrobial activity associated with extracellular matrices. Tissue Eng. 8, 63–71 (2002).

Brennan, E. P. et al. Antibacterial activity within degradation products of biological scaffolds composed of extracellular matrix. Tissue Eng. 12, 2949–2955 (2006).

Brown, B., Lindberg, K., Reing, J., Stolz, D. B. & Badylak, S. F. The basement membrane component of biologic scaffolds derived from extracellular matrix. Tissue Eng. 12, 519–526 (2006).

Wiseman, O. J., Fowler, C. J. & Landon, D. N. The role of the human bladder lamina propria myofibroblast. BJU Int. 91, 89–93 (2003).

Chun, S. Y. et al. Identification and characterization of bioactive factors in bladder submucosa matrix. Biomaterials 28, 4251–4256 (2007).


4.8D: Extracellular Matrix of Animal Cells - Biology

Within tumors, intricate crosstalk between cancer cells and the surrounding microenvironment supports cancer initiation and progression. Importantly, these interactions not only shape the development of the primary tumor but also are required at secondary sites to develop a microenvironment permissive to metastatic growth. This appreciation of the dynamic cancer-stroma interactions in tumor progression has led to a transition from traditional in vitro assays to more complex in vivo models to faithfully embrace the intricacy of cancer. In these models, intravital imaging has been used to dissect the molecular events governing cancer progression and revealed unprecedented information on the behavior of cells in their native environment, both within primary tumors and at distant metastatic sites. In combination with traditional and static approaches used in cancer research, intravital imaging has significantly expanded our understanding of the complexity of cancer biology, as it allows us to directly image the spatiotemporal dynamics of cancer progression in live settings and at the whole-organ, cellular, subcellular, and molecular levels. Here, we outline the latest discoveries facilitated by intravital imaging of tumors, which could not otherwise be achieved in vitro, and discuss how intravital imaging techniques used in other disease contexts could be repurposed for cancer research.

Imaging the tumor vasculature to study cancer growth and dissemination

Cancer cells use and co-opt the surrounding stroma to promote their expansion and dissemination. Tumor-associated blood vessels serve a dual function during cancer development: they provide tumor tissue with essential oxygen and nutrients but can also act as carriers for circulating cancer cells. While various models have been developed in vitro for studying microvasculature systems 1 , 2 , several intravital imaging tools, such as fluorescent proteins or nanoparticles, have been employed to understand the interactions between cancer cells and blood vessels in live settings, an aspect that cannot be recapitulated in vitro 3 – 6 . For example, fluorescently labeled lectins, such as Lens culinaris agglutinin, have been developed to selectively bind to endothelial cells 3 , 4 . Intravenous co-injection of agglutinin and fluorescently labeled cancer cells was recently used with intravital imaging of the embryonic chicken chorioallantoic membrane (CAM). This is a surrogate assay for the study of cancer cell extravasation and metastatic colonization and has recently provided insight into the time course and molecular mechanisms involved in cancer cell extravasation 3 , 4 . Here, the authors demonstrated that intravascular cancer cells initially move along the luminal endothelium in an amoeboid manner and subsequently start to extend protrusions in-between endothelial cells into the extravascular stroma. Cancer cells then gradually push through endothelial cell-cell junctions, in some cases even displacing endothelial cells 4 . Interestingly, invadopodia marker proteins such as cortactin or MT1-MMP were shown to be localized at the protrusions of extravasating cancer cells, and knockdown of these markers impaired cell extravasation and the formation of metastatic colonies within the CAM 4 . In line with this, tail-vein injection of invadopodia-deficient cells into mice resulted in a decreased number of lung metastases, showing that invadopodia are a key feature for transendothelial cancer cell migration 4 . Similarly, providing intravascular cancer cells in the CAM assay with hyaluronic acid, which is a component of the extracellular matrix (ECM) overexpressed in many tumor types 7 – 9 , led to increased cell extravasation 3 . Using this probe therefore demonstrated that the ECM not only represents a physical barrier against chemotherapy delivery 10 but can also be co-opted by cancer cells for secondary site colonization.

Fluorescent dextrans and quantum dot (QD) nanoparticles are also commonly used to visualize blood vessels. More recently, they have been employed during in vivo cancer research to investigate vascular integrity in live tumor tissues 11 , 12 . For example, intravital time-course imaging of QDs in the MMTV-PyMT mouse model of breast cancer allowed Ormandy and colleagues to demonstrate that cancer cells at the primary site can use the surrounding blood vasculature during the progression of invasive and metastatic cancer 13 . Here, ELF5 induction resulted in QD leakage and accumulation within the interstitial space, in line with the formation of hemorrhagic tumors, and increased the number of lung metastases ( Figure 1A , blood vessels in red, note the signal in areas around leaky vessels in PyMT/ELF5 mice 13 ). Furthermore, we previously used QDs to map the vascularization of pancreatic subcutaneous xenograft tumors and showed in vivo that Src activity and drug-mediated Src inactivation in cancer cells correlate with their position relative to intratumoral blood vessels 11 . New organic QDs with improved biocompatibility, stability, and two-photon absorption cross-section and fluorescently tagged viral nanoparticles have recently been developed for real-time intravital mapping of the blood vasculature in vivo 14 , 15 . Fluorescently labeled red blood cells and mice with fluorescently labeled endothelial cells were also engineered to mark the blood vasculature in vivo 16 – 18 , and together with QDs and dextran, these approaches are likely to improve our understanding of how the tumor-associated vasculature supports cancer progression.

Figure 1. Intravital imaging of the ancillary mechanisms promoting cancer progression.

A . Quantum dot (QD) imaging of angiogenesis and leaky tumor vasculature. Adapted from 13 . B . Tracking of photo-converted neutrophils migrating through lymphatic networks. Adapted from 38 . C . Identification of dormant myeloma cells homed into the bone niche. Adapted from 48 . D . Direct visualization of local and systemic transfer of extracellular vesicles and exosomes between different cellular compartments. Adapted from 60 . E . Second harmonic generation (SHG) analysis of collagen crosslinking to identify new regulators of extracellular matrix (ECM)-driven aggressiveness. Adapted from 74 . F . Longitudinal monitoring of chemotherapy pharmacokinetics and targeting through an optical window. Adapted from 93 . G . Dissection of spatiotemporal dynamics of molecular events driving cancer invasion and dissolution in native tissues using reporter mice. Adapted from 96 and 103 . Abbreviations: CAF, cancer-associated fibroblast GFP, green fluorescent protein.

The lymphatic system presents another route of cancer cell dissemination. For example, Das et al. recently used intravital imaging of melanoma cells injected into the mammary fat pad with a lymphatic tracer dye to visualize cancer cell migration towards tumor-draining lymph nodes 19 . The authors demonstrated that lymphatic sinuses of the lymph nodes, but not peripheral lymphatics, secrete CCL8, which activates CCR1 on the cancer cell compartment to permit entry into the lymph node 19 . Inhibition of CCR1 did not impair primary tumor cells from entering the lymphatic system but blocked their exit into the lymph node and arrested the circulating cells within nearby lymphatic vessels. This indicates that lymphatic cancer cell dissemination not only occurs through passive transport but also is supported by paracrine chemotactic signaling 19 . Recently, a transgenic reporter of lymphatic vessels was generated by crossing LSL-tdTomato mice with Prox1-Cre-ERT2 mice to induce fluorescent reporter expression in lymphatic vessels and map cell trafficking within lymphatic networks 20 . While the authors used this model to track dendritic cells entering tdTomato-expressing lymphatic vessels upon acute inflammation in vivo , this technology could be repurposed for future use in cancer research to watch circulating tumor cells disseminating through the lymphatic system.

Imaging the tumor-associated immune system

During cancer progression, tumor cells interact with and manipulate the immune system to facilitate their growth and escape from cell death 21 – 24 . Here, dual intravital imaging of leaky blood vessels and immune cells has been used to identify novel mechanisms of drug action. In particular, the antitumor activity of bisphosphonates, which are commonly used in skeletal diseases, such as osteoporosis 25 , has been explored in a 4T1 mammary tumor mouse model 26 . Here, it was demonstrated that fluorescently labeled bisphosphonates enter the primary tumor site via the leaky vasculature and bind to microcalcifications within the tissue. Bisphosphonates were then incorporated by tumor-associated macrophages (TAMs), and the authors suggest that this might impair the function of TAMs 26 , which have been shown to potentiate tumor progression 27 . Thus, intravital imaging allowed the authors to delineate an unknown mechanism of action underlying the partial benefits of bisphosphonate treatment in breast cancer patients. In line with this, TAMs have also been identified in the tumor microenvironment of metastasis (TMEM), a hotspot of vascular permeability characterized by the physical interaction among tumor cells, TAMs, and endothelial cells 28 . Intravital imaging of blood vasculature using QDs and fluorescent dextran demonstrated that Tie2 hi -expressing TAMs induce transient vascular leakage via vascular endothelial growth factor A (VEGFA) signaling, thereby facilitating tumor cell intravasation. Interestingly, intravital imaging also showed that transendothelial migration preferentially occurred in regions containing a TMEM, and specifically targeting this site could slow down the spread of cancer cells 28 . Intravital imaging has also been used recently to compare the motility of two immune effector cell types, natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) 29 . Here, the authors showed that while NK cells form short and fast contacts with tumor cells independent of calcium signaling, CTLs form long-lasting contacts with tumor cells that require calcium influx into CTLs. Interestingly, both cell types were shown to require calcium influx for efficient killing 29 , thus intravital imaging has provided new insights into the cell-type-specific interactions between tumor cells and the immune system which are needed for specific and efficient killing of tumor cells to occur and which cannot be mimicked faithfully in vitro .

On a similar note, using intravital imaging, Moalli et al. characterized a potential pathway through which tumor-derived antigen is locally processed and presented to generate a systemic immune response 30 . Injection of B16.F10 melanoma cells, transfected with tdTomato as a surrogate tumor-derived antigen, into the mouse footpad led to a robust immune response after 30 days measured by high titers of anti-B16.F10-tdTomato IgG 30 . Imaging of tumor-draining lymph nodes showed that tdTomato was localized in macrophages in the lymphatics and also in follicular dendritic cells (FDCs). Using mouse models of macrophage, FDC, or B-cell deficiency, the authors suggest that tdTomato is taken up by macrophages and subsequently localizes with FDCs, which are then scanned by B-cells, generating a systemic immune response 30 . Similarly, intravital imaging of mCherry-expressing mammary tumors was used to characterize antigen presentation at the tumor site 31 . Here, the authors showed that a subset of myeloid cells function as tumor dendritic cells by taking up and presenting tumor-derived antigen to CTLs. Interestingly, it was shown that CTLs engage with the antigen-presenting cells and subsequently become arrested in this engagement, potentially inhibiting cytolytic effects and tumor rejection. The authors suggest that tumor immunotherapy may help release the CTL blockade following their initial attraction and clustering with antigen-presenting cells at the tumor site 31 . Similarly, Boissonas et al. showed by intravital imaging that infiltrating T-lymphocytes can become trapped with tumor dendritic cells following chemotherapy, suggesting that tumor dendritic cells can function as a sink that retains the T-cell-driven anti-tumor immune response 32 . These findings enhance our understanding of the immune response to cancer development both at primary and metastatic sites, thus intravital imaging may help pave the way to the development of new presentation-derived therapeutics. For example, intravital imaging in the MMTV-PyMT mouse model of breast cancer enabled the identification of a type of macrophage-dendritic cell (M-DC) 33 . Here, the authors used fluorescent dextran to label M-DCs and revealed that the depletion of M-DCs decreases tumor growth and metastasis and could therefore present a promising future target 33 . Similarly, recent intravital imaging of CTL intratumoral migration in vivo revealed that treatment with anti-CD137 mAb prolongs the interaction between CTLs and cancer cells, thereby improving the antitumor CTL activity 34 . This is in parallel with recent improvements in anti-PD1 immunotherapy to educate the immune system to recognize and kill melanoma cells 35 and may represent a promising approach for the improvement of immune-based therapeutics in multiple cancer types.

Several fluorescent reporter systems to specifically label and track immune cells within native tissues have been developed recently. One such example is the Catchup mouse model 36 , wherein a bicistronic cassette of Cre and tdTomato was engineered to be expressed under the neutrophil-specific locus Ly6G. Using this tool, the authors tracked neutrophil migration and studied neutrophil-specific gene functions in vivo . Similarly, a transgenic mouse with ubiquitous expression of Kikume, a green fluorescent protein (GFP) that can be irreversibly photo-converted to red via violet light excitation, was used to characterize dendritic cell 37 and neutrophil migration 38 in vivo ( Figure 1B , single-cell tracking of neutrophils 38 ). For example, upon bacterial infection, neutrophils were recruited to the mouse ear and were photo-converted. Further intravital imaging allowed the authors to track the photo-converted cells and to identify and map new patterns of neutrophil migration and homing into the lymph nodes 38 . Another example is the MacGreen transgenic reporter mouse in which c-fms-driven GFP expression is targeted to macrophages, trophoblasts, and granulocytes 39 . Using this reporter, Pai et al. could track circulating leukocytes during cerebral malaria pathogenesis and identified plasmodium-specific CD8+ T lymphocytes as important regulators of this disease 40 . Crossing these reporter animal models with mouse models of cancer may provide much-needed insights into how cancer cells manipulate and interact with the host immune system to promote tumor progression. For example, intravital imaging may allow us to identify the migration routes of immune cells during cancer progression and treatment or to characterize tumor immune subtypes 41 , 42 in a dynamic manner to better inform on immunotherapies in cancer, a feature of cancer progression that cannot be modeled or assessed accurately in vitro .

Cancer-fibroblast interactions facilitate tumor progression

Fibroblasts are also frequently recruited to tumor sites, and intravital imaging has recently been used to show that stromal fibroblasts can regulate overall tumor response to chemotherapy. For example, intravital imaging of a xenograft model of melanoma through an optical window demonstrated paradoxical activation of cancer-associated fibroblasts (CAFs) at the primary site upon treatment with Braf inhibitors, thereby leading to increased stiffening of the ECM compartment 43 . Here, the authors show that the stiffened ECM in turn activated adhesion-mediated signaling pathways, such as focal adhesion kinase (FAK), to promote cancer cell survival and so decrease anti-Braf treatment efficacy 43 . Interestingly, impairing cellular adhesion tension through FAK inhibition reduced the safe haven provided by the ECM and resulted in a significantly enhanced response to chemotherapy 43 .

Similarly, Lee et al. used in vivo whole-body bioluminescence imaging to investigate the mechanisms of resistance to anti-insulin-like growth factor (anti-IGF) treatment with cixutumumab 44 , which recently showed limited efficacy in clinical trials 45 , 46 . Here, the authors demonstrated that upon treatment with cixutumumab, cancer cells underwent a protective reprogramming characterized by increased production of IGF, which in turn led to the recruitment and activation of host fibroblasts to the primary site through IGF-2R-dependent paracrine signaling. Activated fibroblasts were then shown to secrete pro-angiogenic factors and to potentiate metastasis and disease relapse 44 . Their findings also correlated with changes in the tumor microenvironment of patients undergoing anti-IGF-based therapies 44 , suggesting that preventing fibroblast activation can impair extrinsic mechanisms of chemoresistance and in turn improve cixutumumab efficacy.

Intravital imaging has also been used to implicate stromal fibroblasts in cancer cell dormancy, an important cause of disease relapse, which remains poorly understood 47 . In a recent study, Lawson et al. developed an approach for longitudinal intravital imaging of myeloma cells that had lodged within dense bone tissue 48 . Using a dye-dilution system, the authors were able to label and track slowly proliferating, dormant cells over time and showed that these cells preferentially lodge in direct contact with the endosteal bone surface and interact with host bone cells to establish a protective niche for persistence of metastasis (see Figure 1C showing dormant cells [red] lodged at the surface of the bone [white] and proliferating cells [green] 48 ). Importantly, this study demonstrated that cell dormancy is a reversible state, which can be turned “off” and “on” by signals emanating from host osteoblasts and osteoclasts. The authors suggest that using bone-active drugs to either prevent the reactivation of dormant cells or take cells out from dormancy before treating them with chemotherapy could improve outcome and reduce disease relapse. Their findings present new opportunities for the treatment of metastatic cancers with a bone tropism such as breast, prostate, or kidney cancer 48 .

Tumor cells have also been shown to co-opt fibroblasts to promote cancer spread, and recent in situ imaging of secondary organ colonization has been used to reveal how host fibroblasts are implicated in the preparation of the metastatic niche 49 . In an orthotopic model of breast cancer, dual monitoring of metastatic initiating breast cancer cells and lung fibroblasts recently revealed that reciprocal interactions between the two cell types are required for successful establishment of lung metastases. Here, the authors demonstrate that a biphasic intercellular crosstalk progressively modifies both compartments. Briefly, activation of a fibrotic program in the fibroblast population led to the initiation of a mesenchymal-to-epithelial transition within the cancer cell compartment, promoting the onset of metastasis 49 . Taken together, these studies suggest that preventing fibroblast activation and reprogramming driven by tumor cells during cancer progression may help improve sensitivity to chemotherapy and impair cancer dissemination. Intravital imaging of secondary sites prone to metastasis is required to directly visualize the stages of metastatic colonization however, long-term and deep imaging of metastatic organs remains technically challenging. Optical imaging windows now enable longitudinal and deep imaging of events occurring at both primary sites and secondary organs such as the liver, spleen, kidney, and pancreas 50 , 51 . For instance, monitoring the early events promoting the formation of the liver metastatic niche was achieved using optical imaging windows 52 . Interestingly, this study demonstrated that single extravasated cells are initially highly motile and proliferative and form pre-micrometastases within the liver before merging into micrometastases with reduced migration. Importantly, impairing early tumor cell migration significantly reduced the metastatic burden 52 . Similarly, the formation of the liver metastatic microenvironment and response to chemotherapy has been studied using longitudinal scanning multiphoton microscopy in an intrasplenic model of colorectal cancer 50 and informed on the response of metastatic cells to chemotherapy.

One limitation to longitudinal intravital imaging is the movement of live tissue, such as heart or lung, which can perturb high-resolution intravital imaging, and current research focuses on motion compensation systems to correct for tissue movement 53 – 55 . Additionally, the probability of imaging an invasive or metastatic event can be considered very low however, optogenetic intravital imaging can be used to specifically activate or inhibit signaling pathways and subsequently trigger such an event.

Intercellular crosstalk is supported by extracellular vesicles

Reciprocal interactions between cancer and stromal cells require an exchange of information, for example, in the form of physical cell-cell interaction or secretion of protein ligands or extracellular vesicles (EVs). Direct visualization of signal transmission between cancer cells and the host environment has long been technically challenging however, the recent development of new intravital imaging tools has helped elucidate the mechanisms which enable intercellular exchange of information within both primary and metastatic sites. Recent studies showed that cancer cells can manipulate host stromal cells through the local and systemic transfer of exosomes and other EVs 56 – 58 . For instance, live imaging of a chicken embryo model of fibrosarcoma indicated that exosomes promote cancer cell-ECM adhesion assembly and are required for persistent cell movement 59 . In addition, elegant in situ studies demonstrated that exosomes secreted from primary cancer cells localize at secondary metastatic sites, fuse with host cells, and can �ucate” secondary organs through the activation of fibrotic and inflammatory programs 56 , 57 . In line with this study, direct intravital imaging of exosome secretion and uptake by different cell populations 60 , 61 has recently been achieved. Here, Zomer et al. developed a Cre-loxP-based system whereby cells that take up Cre(+) EVs exhibit a change in color (see Figure 1D showing Cre[+] cells [blue], reporter cells that incorporated Cre[+] EVs [green], and reporter cells that did not 60 ). With this approach, the authors demonstrated that EVs are locally and systemically transferred from aggressive cancer cells to less malignant cancer cells within the same mouse to coordinate a whole-body systemic metastatic program in vivo and to enhance the overall metastatic ability of the tumor 60 , 61 . Recent findings also demonstrate that mitochondrial DNA (mtDNA) can be transferred from host stromal cells to cancer cells. Here, the authors genetically manipulated melanoma and breast cancer cells to lack mtDNA and showed in situ that they can acquire host mtDNA to restore mitochondrial functions such as bioenergetic dynamics and respiration. In addition, incorporation of host mtDNA by cancer cells led to increased tumor growth and metastatic spread, demonstrating that tumor cells can take up material from the host to drive cancer aggressiveness 62 , 63 . Interestingly, Osswald et al. used in vivo multiphoton scanning of astrocytomas over a year to study a novel mechanism of intercellular connection 64 , wherein tumor cells in astrocytomas use ultra-long protrusions (>500 μm in length) to form a network of multi-cellular communication. The authors show that this network supports tumor cell invasion and proliferation and protects cancer cells against radiotherapies 64 . Future developments in intravital imaging to directly visualize mechanisms of cell-cell interaction may help us understand how cancer cells and host tissues interact and together drive cancer aggressiveness, and in the future may help us to uncouple this support mechanism.

Imaging biomechanical properties of the extracellular matrix

Over the last decade, intensive work has shown that ECM abundance and features, such as stiffness, topography, and porosity, contribute to tumor cell proliferation, invasion, and chemoresistance 65 – 72 . Multiphoton imaging technologies, such as second harmonic generation (SHG) imaging 73 , have been used to study the modulation of ECM characteristics during cancer progression and have recently identified new regulators of biomechanical tissue properties (see Figure 1E showing collagen deposition in in vitro 3D organotypic fibroblast-collagen matrices upon induction of P-Rex, a guanine exchange factor for Rac1 74 ). For instance, the actin cytoskeleton and a number of its regulatory proteins, such as the family of Rho GTPases, are known to govern the remodeling of the ECM 69 , 75 – 77 , and live SHG imaging has provided new insights into the tight regulation of Rho GTPases in vivo . In collaboration with Samuel and colleagues, we helped identify the intracellular signaling protein 14-3-3 ζ as a novel negative regulator of Rho-kinase-driven ECM stiffening in wound healing 78 . Here, live monitoring of stromal fibroblasts coupled with SHG imaging of collagen fibers in a 3D in vitro environment was used to show that loss of 14-3-3 ζ in dermal fibroblasts impairs their ability to remodel collagen and to stiffen the ECM, and such effects were also seen in ex vivo animal samples 78 . Interestingly, this study also showed in squamous cell carcinoma that 14-3-3 ζ is downregulated while collagen deposition is increased, suggesting that ROCK signaling is no longer restrained and controlled in vivo in this disease 69 , 78 , 79 . These findings suggest new therapeutic options for re-purposing 14-3-3 ζ-based treatments to facilitate uniformed and controlled wound healing 78 , which in future can also be used in the context of cancer to re-establish normal tissue homeostasis of solid tumors 69 , 80 , 81 .

The hypoxic tumor environment was also recently identified as a novel regulator of the ECM ultrastructure and stiffness at both primary and metastatic sites 82 , 83 . For example, hypoxia was shown to inhibit prolyl hydroxylase domain protein 2 (PHD2) in CAFs in vitro and in vivo, leading to a reversion of CAF activation and a decrease in their ability to remodel and stiffen the ECM 82 . In addition, proteins secreted from hypoxic tumors were demonstrated to prepare and activate the ECM of future metastatic sites. One such example is the enzyme lysyl oxidase (LOX), which is upregulated in bone tropic breast cancer cells 83 . In vivo, injection of LOX resulted in the formation of osteolytic lesions and in turn provided circulating breast cancer cells with a focal pre-metastatic niche for bone colonization, whereas LOX targeting with a blocking antibody partially reverted this phenotype and decreased tumor burden, as visualized by whole-body in vivo imaging 83 . Intravital SHG imaging has also been used to directly monitor changes of the ECM structure and content during cancer progression in live settings. For example, Walsh et al. performed intravital SHG imaging of breast cancer xenografts to study the effects of trastuzumab treatment on the ECM 84 . Interestingly, their study demonstrated that trastuzumab induces changes in collagen density and alignment and thereby identified a non-cellular response to drug treatment 84 . In addition, longitudinal SHG imaging of orthotopic breast xenografts was performed at the tumor margin to identify the key components of the tumor microenvironment that modulates cell invasion 85 . Here, the authors used dual imaging of single cells and collagen fibers and showed that slow-locomotion breast cancer cells form invadopodia to remodel and stiffen the collagen matrix while they move through the surrounding tissue. Further use of intravital SHG imaging will provide important insights into the role of the ECM and its manipulation during tumor progression.

Rapidly developing intravital technologies and tools have provided unprecedented insights into cancer complexity and have also opened up promising avenues for pre-clinical cancer research. For example, SHG imaging has recently been translated to study the properties of the ECM in biopsy samples of cancer patients. For instance, in the context of pancreatic cancer, we recently used SHG imaging to analyze the properties of the ECM in a human pancreatic tissue microarray (>80 samples) and detected a positive correlation between fibrillar collagen abundance, tumor stage, lymph node spread, and vascular invasion, suggesting that fine-tuned targeting of collagen crosslinking may be a valid approach in this disease 86 . In line with this study, biophysical analysis of collagen remodeling was conducted in human breast cancer biopsies (>20 samples) and revealed a progressive increase of collagen reorganization and orientation as invasive cancer lesions develop 87 . Similarly, in a cohort of matched human breast tissues with areas of high and low mammographic density from the same patient (>15 samples), we analyzed ECM organization by gray-level co-occurrence matrix (GLCM), an image texture-based approach used to quantify the organization of collagen fiber networks 88 . In this study, Britt and colleagues demonstrated that increased deposition and crosslinking of collagen fibers correlates with a high risk of developing breast cancer 88 . Taken together, these studies along with our knowledge from intravital animal models indicate that upon acquisition of human biopsies, characterization of ECM abundance and crosslinking using medium-throughput SHG imaging can potentially be used as a biomarker to predict patient prognosis and tumor stage. Moreover, the development of new probes to directly image distinct components of the ECM such as hyaluronan 3 , 89 , elastin 90 , or fibronectin 91 is likely to facilitate our understanding of the role of the ECM in cancer development and may help us improve therapies targeting specific components of the ECM.

New tools for live, intravital, and in situ imaging in translational cancer research

Fluorescence-based biosensors are emerging as a reliable tool to dissect mechanisms of drug target activity and chemoresistance. In a large panel of MEK inhibitor (MEKi)-resistant cell lines, live imaging of extracellular signal-regulated kinase (Erk) and S6K fluorescent biosensors was used to interrogate the molecular bases of resistance to MEKi in Kras-mutant and Braf-mutant cancer cell lines in vitro . Here, the authors showed that upon treatment with MEKi, Erk and PI3K pathways can maintain mTORC1 activity and in turn promote cell growth, thereby leading to resistance to treatment 92 . Furthermore, fluorescently tagged drugs were used to decipher mechanisms of drug resistance. For instance, a fluorescent analog of eribulin was designed to monitor in vivo drug pharmacokinetics. Here, the authors engineered a portion of tumor cells to express multidrug-resistance 1 (MDR1)-mApple fusion protein, and dual imaging of eribulin and MDR1-mApple demonstrated that resistance to eribulin was directly correlated with vascular architecture and MDR1-mediated drug efflux. This study also demonstrated that inhibition of MDR1 reversed the multidrug-resistant phenotype and improved eribulin efficacy 93 ( Figure 1F showing fluorescent eribulin [green] diffusing into tumor tissue and being incorporated only by cancer cells not expressing MDR1-mApple fusion protein at 1 and 2 hours following treatment with eribulin 93 ).

Taking these approaches further, for the assessment of whole-tissue or whole-body protein activity, transgenic mice have been generated with ubiquitous or Cre-inducible expression of reporters of the activity of Erk, PKA, Rac1, cAMP, or cell cycle progression 94 – 99 ( Figure 1G , map of Rac activity where red and yellow mark low Rac activity and blue and green highlight high Rac activity 96 ). Crossing these biosensor mice with animal models of cancer allows us to dissect the spatiotemporal mechanisms of the molecular events driving cancer in native tissues. For example, Kumagai et al. recently crossed their Erk biosensor mouse with a mouse model of mammary tumor formation and described a stable heterogeneous pattern of Erk activity 100 . Interestingly, the authors showed that cells with low Erk activity were more successful in forming tumor spheres in vitro and expressed high markers of mammary cancer stem cells compared to cells with high Erk activity 100 . These findings indicate that tumor heterogeneity in Erk activity may be beneficial to establish cancer stem cells with low Erk activity for self-renewal, whereas high Erk activity supports rapid growth and expansion 100 . Similarly, Erk pulsing and propagation dynamics emanating from the skin and hair follicle have also recently been demonstrated in vivo 101 and have significant implications for future research in melanoma 102 .

Another recent example of biosensor mouse imaging in cancer is our E-cadherin-GFP mouse, which enabled us to perform photobleaching experiments in vivo to monitor cell-cell junction dynamics ( Figure 1G , E-cadherin-GFP expression in cell-cell junctions of the lactating mammary gland 103 ). Here, we used fluorescence recovery after photobleach (FRAP) and fluorescence loss in photobleach (FLIP) imaging along with kymograph analysis to quantify E-cadherin mobility of healthy and diseased tissue. Using this approach, we could correlate high E-cadherin mobility in the cell membrane with a decrease in junction strength and integrity and an increase in cell invasiveness 103 . Crossing this mouse with a genetically engineered model of pancreatic cancer allowed us to recapitulate the full spectrum of pancreatic cancer progression and to dissect the genetic stages of early cancer dissolution. This mouse was also used as a tool for drug discovery by testing new anti-invasive agents, such as dasatinib, in pancreatic cancer, where we demonstrated that dasatinib is able to strengthen cell-cell junction integrity in line with decreased invasiveness in this setting 103 . This is in line with current clinical assessment in patients and its known effectiveness in the KPC pancreatic cancer mouse model 104 .

Mouse models with ubiquitous expression of molecular reporters can now be used to monitor events in a large range of organs and diseases however, due to light scattering within tissues, the imaging depth with current two-photon lasers is limited to several-hundred μm, limiting intravital imaging of large organs and tumors. Current multiphoton setups include three-photon lasers in combination with optical parametric oscillators (OPOs) that increase the excitation wavelength, as red and near-infrared light can penetrate deeper into tissue and reduces tissue scattering 105 , 106 . This requires the use of fluorescent proteins that can be excited with near-infrared wavelengths, such as iRFP or iRFP variants, which have been recently described 107 , 108 . Furthermore, computational models, such as adaptive optical correction, have been used to overcome light scattering and to increase imaging depth 109 . Another imaging technique, called photoacoustic tomography (PAT), makes use of the phenomenon that photon absorption forms pressure waves that can be detected. Although PAT increases imaging depth, it strongly reduces image resolution, which can be partially overcome by the use of near-infrared fluorescent proteins 110 , 111 . Furthermore, current proceedings to reduce the distal optics and mechanical components of intravital microscopes 112 – 114 should move the field towards intravital endoscopy of cancer biology 115 .

Lastly, optogenetics, which rely on the inherent properties of light to observe and accurately control complex biochemical and signaling events 116 , is emerging as another promising tool to interrogate cancer dynamics. Optogenetics allows researchers to manipulate gene expression or the activity of cellular signaling pathways and has recently enabled photocontrol of proteins with subcellular resolution. These approaches have been used to modify protein conformation 117 , stimulate DNA binding 118 , control enzymatic 119 or receptor tyrosine kinase activity 120 , induce protein localization 121 , manipulate protein-protein interactions 122 , and study signaling pathway events 123 , 124 . For instance, optogenetics was used to demonstrate that localized Rac1 activity is sufficient to produce precisely regulated cell protrusion events to control directed cell motility in vivo 125 – 128 . Most importantly, optogenetics may enable us to modulate cancer-related signaling pathways in a defined spatiotemporal manner and allow us to follow the fate of de-regulated cells in their in situ environment. In summary, intravital imaging has demonstrated its capacity to allow us to explore the ancillary mechanisms supporting cancer progression and provide novel routes for the development of future therapeutics to target and impair these support mechanisms.

CAF, cancer-associated fibroblast CAM, chorioallantoic membrane CTL, cytotoxic T-lymphocyte ECM, extracellular matrix ERK, extracellular signal-regulated kinase EV, extracellular vesicle FAK, focal adhesion kinase FDC, follicular dendritic cell FLIP, fluorescence loss in photobleaching FRAP, fluorescence recovery after photobleaching GLCM: gray-level co-occurrence matrix IGF, insulin-like growth factor LOX, lysyl oxidase M-DC, macrophage-dendritic cell MDR1, multi-drug resistance 1 MEKi, MEK inhibitor mtDNA, mitochondrial DNA NK cell, natural killer cell OPO, optical parametric oscillator PAT, photoacoustic tomography PHD2, prolyl hydroxylase domain protein 2 QD, quantum dot SHG, second harmonic generation TAM, tumor-associated macrophage TMEM, tumor microenvironment of metastasis VEGFA, vascular endothelial growth factor A.


Reichert, J. C. et al. The challenge of establishing preclinical models for segmental bone defect research. Biomaterials 30, 2149–2163, doi: 10.1016/j.biomaterials.2008.12.050 (2009).

Chimutengwende-Gordon, M. & Khan, W. S. Advances in the use of stem cells and tissue engineering applications in bone repair. Current stem cell research & therapy 7, 122–126 (2012).

Oryan, A., Alidadi, S., Moshiri, A. & Maffulli, N. Bone regenerative medicine: classic options, novel strategies, and future directions. Journal of orthopaedic surgery and research 9, 18, doi: 10.1186/1749-799X-9-18 (2014).

Saran, U., Gemini Piperni, S. & Chatterjee, S. Role of angiogenesis in bone repair. Archives of biochemistry and biophysics 561, 109–117, doi: 10.1016/j.abb.2014.07.006 (2014).

Leferink, A. et al. Engineered micro-objects as scaffolding elements in cellular building blocks for bottom-up tissue engineering approaches. Advanced materials 26, 2592–2599, doi: 10.1002/adma.201304539 (2014).

De Giglio, E. et al. Development and characterization of rhVEGF-loaded poly(HEMA-MOEP) coatings electrosynthesized on titanium to enhance bone mineralization and angiogenesis. Acta biomaterialia 6, 282–290, doi: 10.1016/j.actbio.2009.07.008 (2010).

McFadden, T. M. et al. The delayed addition of human mesenchymal stem cells to pre-formed endothelial cell networks results in functional vascularization of a collagen-glycosaminoglycan scaffold in vivo . Acta biomaterialia 9, 9303–9316, doi: 10.1016/j.actbio.2013.08.014 (2013).

Jabbarzadeh, E. et al. Induction of angiogenesis in tissue-engineered scaffolds designed for bone repair: a combined gene therapy-cell transplantation approach. Proceedings of the National Academy of Sciences of the United States of America 105, 11099–11104, doi: 10.1073/pnas.0800069105 (2008).

Viateau, V. et al. Use of the induced membrane technique for bone tissue engineering purposes: animal studies. The Orthopedic clinics of North America 41, 49–56 table of contents, doi: 10.1016/j.ocl.2009.07.010 (2010).

Thery, C., Ostrowski, M. & Segura, E. Membrane vesicles as conveyors of immune responses. Nature reviews. Immunology 9, 581–593, doi: 10.1038/nri2567 (2009).

van der Pol, E., Boing, A. N., Harrison, P., Sturk, A. & Nieuwland, R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacological reviews 64, 676–705, doi: 10.1124/pr.112.005983 (2012).

Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and friends. The Journal of cell biology 200, 373–383, doi: 10.1083/jcb.201211138 (2013).

Quesenberry, P. J. et al. Cellular phenotype and extracellular vesicles: basic and clinical considerations. Stem cells and development 23, 1429–1436, doi: 10.1089/scd.2013.0594 (2014).

Quesenberry, P. J. & Aliotta, J. M. Cellular phenotype switching and microvesicles. Advanced drug delivery reviews 62, 1141–1148, doi: 10.1016/j.addr.2010.06.001 (2010).

Chen, J. et al. Proangiogenic compositions of microvesicles derived from human umbilical cord mesenchymal stem cells. PloS one 9, e115316, doi: 10.1371/journal.pone.0115316 (2014).

Zhang, H. C. et al. Microvesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo . Stem cells and development 21, 3289–3297, doi: 10.1089/scd.2012.0095 (2012).

Bian, S. et al. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. Journal of molecular medicine 92, 387–397, doi: 10.1007/s00109-013-1110-5 (2014).

Lopatina, T. et al. Platelet-derived growth factor regulates the secretion of extracellular vesicles by adipose mesenchymal stem cells and enhances their angiogenic potential. Cell communication and signaling: CCS 12, 26, doi: 10.1186/1478-811X-12-26 (2014).

Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A. & Ratajczak, M. Z. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 20, 1487–1495, doi: 10.1038/sj.leu.2404296 (2006).

Lin, S. S. et al. Bone marrow mesenchymal stem cell-derived microvesicles protect rat pheochromocytoma PC12 cells from glutamate-induced injury via a PI3K/Akt dependent pathway. Neurochemical research 39, 922–931, doi: 10.1007/s11064-014-1288-0 (2014).

Bruno, S. et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PloS one 7, e33115, doi: 10.1371/journal.pone.0033115 (2012).

Moon, J. J. & West, J. L. Vascularization of engineered tissues: approaches to promote angio-genesis in biomaterials. Current topics in medicinal chemistry 8, 300–310 (2008).

Potier, E. et al. Prolonged hypoxia concomitant with serum deprivation induces massive human mesenchymal stem cell death. Tissue engineering 13, 1325–1331, doi: 10.1089/ten.2006.0325 (2007).

Sun, L. et al. Serum deprivation elevates the levels of microvesicles with different size distributions and selectively enriched proteins in human myeloma cells in vitro . Acta pharmacologica Sinica 35, 381–393, doi: 10.1038/aps.2013.166 (2014).

Witwer, K. W. et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. Journal of extracellular vesicles 2, doi: 10.3402/jev.v2i0.20360 (2013).

Bruno, S. et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. Journal of the American Society of Nephrology: JASN 20, 1053–1067, doi: 10.1681/ASN.2008070798 (2009).

Narayanan, R., Huang, C. C. & Ravindran, S. Hijacking the Cellular Mail: Exosome Mediated Differentiation of Mesenchymal Stem Cells. Stem cells international 2016, 3808674, doi: 10.1155/2016/3808674 (2016).

Cocucci, E., Racchetti, G. & Meldolesi, J. Shedding microvesicles: artefacts no more. Trends in cell biology 19, 43–51, doi: 10.1016/j.tcb.2008.11.003 (2009).

Mankani, M. H., Kuznetsov, S. A., Marshall, G. W. & Robey, P. G. Creation of new bone by the percutaneous injection of human bone marrow stromal cell and HA/TCP suspensions. Tissue engineering. Part A 14, 1949–1958, doi: 10.1089/ten.tea.2007.0348 (2008).

Janicki, P. et al. Prediction of in vivo bone forming potency of bone marrow-derived human mesenchymal stem cells. European cells & materials 21, 488–507 (2011).

Patel, Z. S. et al. Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model. Bone 43, 931–940, doi: 10.1016/j.bone.2008.06.019 (2008).

Aliotta, J. M. et al. Stable cell fate changes in marrow cells induced by lung-derived microvesicles. Journal of extracellular vesicles 1, doi: 10.3402/jev.v1i0.18163 (2012).

Arslan, F. et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem cell research 10, 301–312, doi: 10.1016/j.scr.2013.01.002 (2013).

Eirin, A. et al. MicroRNA and mRNA cargo of extracellular vesicles from porcine adipose tissue-derived mesenchymal stem cells. Gene 551, 55–64, doi: 10.1016/j.gene.2014.08.041 (2014).

Sabin, K. & Kikyo, N. Microvesicles as mediators of tissue regeneration. Translational research: the journal of laboratory and clinical medicine 163, 286–295, doi: 10.1016/j.trsl.2013.10.005 (2014).

Bernimoulin, M. et al. Differential stimulation of monocytic cells results in distinct populations of microparticles. Journal of thrombosis and haemostasis: JTH 7, 1019–1028, doi: 10.1111/j.1538-7836.2009.03434.x (2009).

Zhang, D. Y., Wang, H. J. & Tan, Y. Z. Wnt/beta-catenin signaling induces the aging of mesenchymal stem cells through the DNA damage response and the p53/p21 pathway. PloS one 6, e21397, doi: 10.1371/journal.pone.0021397 (2011).

Zhang, Z. Y. et al. Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells. Stem cells 27, 126–137, doi: 10.1634/stemcells.2008-0456 (2009).

Hergenreider, E. et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nature cell biology 14, 249–256, doi: 10.1038/ncb2441 (2012).

Sokolova, V. et al. Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids and surfaces. B, Biointerfaces 87, 146–150, doi: 10.1016/j.colsurfb.2011.05.013 (2011).

Wang, Z. X. et al. The Treatment Efficacy of Bone Tissue Engineering Strategy for Repairing Segmental Bone Defects Under Osteoporotic Conditions. Tissue engineering. Part A 21, 2346–2355, doi: 10.1089/ten.TEA.2015.0071 (2015).


Claims

1. An isolated extracellular vesicle (EV), wherein the isolated EV contains one more proteins selected from the group consisting of KRT19, TUBB, TUBB2A, TUBB2B, TUBB2C, TUBB3, TUBB4B, TUBB6, CFL1 (HEL-S-15), VIM, EEF1A1, EEF1A1P5, PTI-1, EEF1A1L14, EEFA2, ENPP1, NT5E, HSPA8 (HEL-S-72p), RAB10, CD44, MMP2, CD109, and DKFZp686P132.

2. The isolated EV of claim 1, wherein the EV contains one or more proteins selected from the group consisting of CD44, CD109, NT5E, MMP2 and HSPA8.

3. The isolated EV of claim 1, wherein the isolated EV is engineered to contain the one or more proteins.

4. The isolated EV of claim 1, wherein the isolated EV is obtained from a cell.

5. The isolated EV of claim 4, wherein the cell is selected from an immortalized cell line or a primary cell.

6. The isolated EV of claim 4, wherein the cell is a mesenchymal stem cell (MSC).

7. The isolated EV of claim 1, wherein the cell is a non-MSC.

8. The isolated EV of claim 7, wherein the non-MSC comprises a fibroblast cell, or a macrophage cell.

9. The isolated EV of claim 4, wherein the isolated EV contains an increased amount of the one or more protein markers compared to the average amount in all EVs obtained from the MSC.

10. The isolated EV of claim 9, wherein the isolated EV contains an at least 20% increased amount of the one or more protein markers.

11. The isolated EV of claim 6, wherein the MSC is isolated from Wharton's jelly, umbilical cord blood, placenta, peripheral blood, bone marrow, bronchoalveolar lavage (BAL), or adipose tissue.

12. The isolated EV of claim 1, wherein the isolated EV is a synthetic exosome produced in vitro.

13. The isolated EV of claim 12, wherein the synthetic exosome is a synthetic liposome.

14. The isolated EV of claim 1, wherein the isolated EV further contains Syntenin-1, Flotillin-1, CD105, and/or major histocompatibility complex class I.

15. The isolated EV of claim 1, wherein the isolated EV further contains a member of the tetraspanin family.

16. The isolated EV of claim 15, wherein the member of the tetraspanin family contains CD63, CD81, and CD9.

17. A method of isolating an extracellular vesicle (EV) having increased potency comprising engineering the EV to contain one or more proteins selected from the group consisting of KRT19, TUBB, TUBB2A, TUBB2B, TUBB2C, TUBB3, TUBB4B, TUBB6, CFL1 (HEL-S-15), VIM, EEF1A1, EEF1A1P5, PTI-1, EEF1A1L14, EEFA2, ENPP1, NTSE, HSPA8 (HEL-S-72p), RAB10, CD44, MMP2, CD109, and DKFZp686P132.

34. A method of treating a disease or condition associated with reduced angiogenesis, acute inflammation, chronic inflammation, apoptosis, mitochondrial dysfunction, fibrosis or vasculopathy, comprising administering to a subject in need thereof isolated extracellular vesicles obtained from mesenchymal stromal cells, wherein the isolated extracellular vesicles comprise extracellular vesicles (EVs) containing one or more proteins selected from the group consisting of KRT19, TUBB, TUBB2A, TUBB2B, TUBB2C, TUBB3, TUBB4B, TUBB6, CFL1 (HEL-S-15), VIM, EEF1A1, EEF1A1P5, PTI-1, EEF1A1L14, EEFA2, ENPP1, NT5E, HSPA8 (HEL-S-72p), RAB10, CD44, MMP2, CD109, and DKFZp686P132.

113. A method of treating or preventing a respiratory disease or disorder, comprising administering to a subject in need thereof an effective dose of an isolated extracellular vesicle (EV), wherein the isolated EV contains one or more proteins selected from the group consisting of KRT19, TUBB, TUBB2A, TUBB2B, TUBB2C, TUBB3, TUBB4B, TUBB6, CFL1 (HEL-S-15), VIM, EEF1A1, EEF1A1P5, PTI-1, EEF1A1L14, EEFA2, ENPP1, NT5E, HSPA8 (HEL-S-72p), RAB10, CD44, MMP2, CD109, and DKFZp686P132.

114. The method of claim 113, wherein the respiratory disease or disorder comprises acute respiratory distress syndrome (ARDS), acute lung disease, asthma, chronic obstructive pulmonary disease, cystic fibrosis, pneumonitis, pulmonary fibrosis, acute lung injury, bronchitis, emphysema, bronchiolitis obliterans, or bronchopulmonary dysplasia (BPD).

115. The method of claim 113, wherein the method treats or prevents respiratory disease or disorder resulting from COVID-19.

116. The method of claim 114, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis.

117. The method of claim 113, wherein the respiratory disease or disorder is the result of an infection, sepsis, acid aspiration, or trauma.

118. The method of claim 113, wherein the infection is a bacterial infection or a viral infection.

119. The method of claim 113, wherein the respiratory disease or disorder is the result of a SARS-CoV-2 infection.

120. The method of claim 113, wherein the method comprises administering EV to a patient at risk of developing respiratory disease or disorder.

121. The method of claim 113, wherein the effective dose of the isolated EV is from 20 to 500 pmol of phospholipids of EVs per kg of subject being treated.

132. The method of claim 113, wherein the isolated EV are administered parenterally.

133. The method of claim 113, wherein the method further comprises administering a phosphodiesterase type-5 (PDE5) inhibitor.

134. The method of claim 133, wherein the PDE5 inhibitor is sildenafil.

135. The method of claim 133, wherein the isolated EV and the phosphodiesterase type-5 (PDE5) inhibitor are administered in separate compositions, substantially simultaneously or sequentially.

136. The method of claim 133, wherein the isolated EV and the phosphodiesterase type-5 (PDE5) inhibitor are administered in the same composition.

137. The method of claim 133, wherein the isolated EV and PDE5 inhibitor are administered in one or more doses.

138. The method of claim 133, wherein the isolated EV and the PDE5 inhibitor are administered at an interval of 6 hours, 12, hours, 24 hours, 48 hours, 72 hours, 4 days, 5, days, 6 days, or once per week.

139. The method of claim 133, wherein the isolated EV is administered in 2 doses, 3 doses, 4, doses, 5 doses, 6 doses, 7 doses, 8 doses, 9 doses, 12 doses, 15 doses, or 18 doses 3 doses, 6 doses, 9 doses, 12 doses, 15 doses, or 18 doses, and wherein the PDE5 inhibitor is administered in 16 doses, 19 doses, 21 doses, 24 doses, 27 doses, 30 doses, 33 doses, 36 doses, 39 doses, 42 doses, 45 doses, 48 doses, 51 doses, 54 doses, 57 doses, 60 doses, 63 doses, or 66 doses.

140. The method of claim 113, wherein the isolated EV is administered once daily for 2 days, for 3 days, for 4 days, for 5 days for 6 days, or for a week.

141. The method of claim 113, wherein the method decreases systolic pulmonary arterial pressure (SPAP) in the subject.

142. The method of claim 113, wherein the method increases alveolar surface area of the lung in the subject.

143. The method of claim 113, wherein the method increases a concentration of blood oxygen in the subject.

144. The method of claim 113, wherein the method reduces inflammation in the lung in the subject.

145. The method of claim 113, wherein the method reduces deposition of extracellular matrix in the bronchoalveolar lavage fluid or in the lung.

146. The method of claim 113, wherein the method improves Fulton's index.

147. The method of claim 113, wherein the subject is a human, a non-human primate, a dog, a cat, a cow, a sheep, a horse, a rabbit, a mouse, or a rat.

148. The method of claim 133, wherein the PDE5 comprises sildenafil, vardenafil, zapravist, udenafil, dasantafil, avanafil, mirodenafil, or lodenafil.